{"entity":{"id":"taofeek-owonikoko","kind":"person","name":"Taofeek K. Owonikoko","aka":[],"tldr":"Medical oncologist who is Executive Director of the NCI-designated Greenebaum Comprehensive Cancer Center at the University of Maryland in Baltimore.","summary":"Taofeek K. Owonikoko, MD, PhD, is Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), a National Cancer Institute-designated comprehensive cancer centre in Baltimore. He holds the Kevin J. Cullen, MD, Distinguished Professorship of Oncology and is Senior Associate Dean of Cancer Programs at the University of Maryland School of Medicine and Associate Vice President of Cancer Programs at the University of Maryland, Baltimore. In his director's welcome he describes a centre with more than 58,000 unique outpatient visits in 2023 that integrates innovative therapies and individualised care with research and education.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Taofeek_Owonikoko","links":[{"label":"Source: UMGCCC Director's Welcome page","url":"https://www.umms.org/umgccc/about/director-welcome"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["maryland-greenebaum"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-wiley","nejm","future-oncology"],"dependsOn":[],"notes":[],"role":"Executive Director, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","institutionId":"maryland-greenebaum","specialisms":["Medical oncology","Thoracic oncology","Cancer centre leadership"],"profiles":[{"label":"UMGCCC Director's Welcome","url":"https://www.umms.org/umgccc/about/director-welcome"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Owonikoko+TK%5BAuthor%5D"}],"papers":[{"title":"Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer","journal":"Cancer","year":2025,"doi":"10.1002/cncr.35738"},{"title":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","journal":"New England Journal of Medicine","year":2025,"doi":"10.1056/nejmoa2502099"},{"title":"IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer","journal":"Future Oncology","year":2025,"doi":"10.1080/14796694.2025.2565995"}]},"route":"/people/taofeek-owonikoko/","neighbours":{"institution":[{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","route":"/institutions/maryland-greenebaum/"}],"journal":[{"id":"cancer-wiley","kind":"journal","name":"Cancer","route":"/journals/cancer-wiley/"},{"id":"future-oncology","kind":"journal","name":"Future oncology","route":"/journals/future-oncology/"},{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}